• No products in the cart.

  • LOGIN

Multidisciplinary management, standards of care, optimal diagnostics, therapies and future perspectives in the care of Colon and Rectal Cancer patients in sub-Saharan Africa.


Lead Faculty: Prof. Fredrick Chite Asirwa MD

Consultant Physician. Medical Oncologist & Hematologist

Executive Director/CEO: International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: director@intercancer.com

Website: www.intercancer.com


This educational activity is provided by the International Cancer Institute (ICI)

Faculty

  1. Prof. Dinesh Pendharkar- Consultant Oncologist
  2. Dr. Verna Vanderpuye- Consultant Radiation Oncologist
  3. Dr. Mary Nyangasi-Public Health & Policy Specialist
  4. Dr. Jabulani Munalula-Colorectal surgeon
  5. Dr. Zipporah Ali- Palliative care specialist
  6. Dr. Kibet Keitany- Anatomic Pathologist
  7. Dr. Clifford Chacha-General Surgeon/ Surgical Oncology
  8. Dr. Abdu Adem Yesufe-Clinical Oncologist
  9. Dr. David Wata- Oncology Pharmacist
  10. Dr. Chizi Kiti-ICI Head, Edu. & Training

This course will be accredited by:

Accredited by KMPDB
Accredited by KMPDB

 

Accredited by KPPB
Accredited by KPPB
Accredited by COC
Accredited by COC

 

 

 

 

 


ICI Education & Training Mission Statement

The ICI Preceptorship Program Mission is to measurably contribute to cancer patients’ safety and health outcomes and to support practice improvement by providing CME/CPD activities that enhance the ability of physicians and other health-care team members to deliver quality and optimal healthcare services.

Purpose

The purpose of ICI Preceptorship Program is to develop educational activities that clearly link the needs of the learner/participants with the planning process, format and delivery of each activity, resulting in high-quality continuing medical education/continued Professional Development opportunities that will increase the knowledge, competence and performance of health-care providers.

Content Areas

The ICI Preceptorship Program activities include practical, evidence-based, best clinical practice information for a broad variety of common oncology and haematology conditions, innovations in primary and specialty patient care in NCDs, new procedural training and speciality fora. The appropriate content for each course is determined based on the results of a practice gap analysis relative to the target audience’s scope of practice, as well as the identified expected outcomes. Content is free of commercial bias. General Target Audience: ICI Preceptorship/CME/CPD activities focus on the needs of generalist and specialist physicians and other multidisciplinary health-care team members at ICI affiliated cancer centers nationally and in sub-Saharan Africa as appropriate.

Type of Activities Provided by ICI

In order to accomplish our educational goals, ICI CME uses a range of activity formats based on the content and desired results of the activity. Current offerings include live and videoconferenced activities, live regularly scheduled series, internet CME activities, enduring materials and hands-on skills workshops. ICI also jointly sponsors activities with regional specialty societies, non-profit educational organizations and government agencies when mutually desired goals and outcomes are best achieved by such relationships.

Expected Results of the Preceptorship Program

ICI Preceptorship/CME/CPD is committed to assessing the impact and effectiveness of its CME/CPD Program. ICI courses are designed to: increase knowledge of new treatments, diagnostic tools and procedures; improve compliance with specific evidence-based standard of care protocols; improve competence, performance and/or patient outcomes; and promote efficient use of resources. We employ assessment methods to evaluate the extent to which our activities result in changes in knowledge, competence and performance. CME activities in conjunction with quality improvement projects have measurable outcomes to report. An emphasis during the planning process is placed on intended learning and desired change in knowledge, competence and performance. The ICI Education and Training Office works in collaboration with other departments/offices of the International Cancer Institute and its partners who are involved and interested in quality improvement processes and patient safety.

Target Audience

The primary target audience for this course comprises the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; urologists; other health care professionals (internists, primary care physicians, pathologists, physicians-in-training, urology nurses, oncology nurses, nurse practitioners, pharmacists, physician assistants and nurse practitioners) involved and/or interested in the therapeutic management of patients with Colon and Rectal Cancer

Statement of Need

New developments in the treatment of colorectal cancer (CRC) are often not widely disseminated, especially in sub-Saharan Africa, resulting in patients not receiving the best or most up-to-date care. Health care providers need current information in all factors related CRC treatment, including screening, diagnosing, surgical and non-surgical strategies and overall management of patients with colorectal cancer. Successful CRC treatment requires complex strategies and it may be difficult for clinicians to select from the various options available for diagnosis and treatment. Opportunities to discuss cases and compare treatment plans with colleagues are necessary for physicians to optimize their care plans through multidisciplinary tumor boards. ICI continues to conduct at least two virtual multidisciplinary tumor boards weekly. This course will augment that educational activity.

LEARNING OBJECTIVES

At the end of this educational activity, participants should be able:

  1. To understand the Epidemiology of Colorectal Cancer (Global)
  2. To understand colorectal cancer prevention and evidence-based screening guidelines
  3. To learn the diagnostics, biological basis, prognostic factors and characterization of colon and rectal cancers, understanding the different biological and pathological subtypes of colon and rectal cancer for the selection of appropriate treatment strategies
  4. To understand the role of Surgery in the management of colon and rectal cancer
  5. To understand that colon and rectal cancer in early stages are treated differently
  6. Evaluate the role of neoadjuvant care, radiotherapy and chemotherapy in rectal cancer
  7. To understand the essentials in the assessment and the value of multidisciplinary management of patients with CRC.
  8. To understand the role of chemotherapy, monoclonal antibodies and targeted therapy in the management of patients with advanced disease and standard of care protocols.
  9. To be knowledgeable about the strengths of, and role of personalized medicine and the importance of offering individualized targeted therapies based on molecular findings such as K-Ras, N-Ras or B-Raf mutations
  10. To be knowledgeable on colorectal cancer related hereditary syndromes, the management of families with these and implications for individual patients
  11. To understand the role of Palliative, supportive and survivorship care in colorectal cancer management
  12. To discuss clinical cases between faculty and participants

Disclosure of Conflicts of Interest

International Cancer Institute (ICI) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of the patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labelled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

The Program

LECTURES

  1. Orientation to the course (Chite) Tuesday 2nd June 2020 4:30-5:00 PM EAT
  2. Epidemiology of colorectal cancer (Global) & Public Health perspectives in cancer control (Nyangasi) Thursday 4th June 2020 4:00-5:30 PM EAT
  3. Screening and diagnostic workup for colorectal cancer (Chacha) 9th June 2020 4:00-5:30 PM EAT
  4. Pharmacology of systemic therapies used in colorectal cancer, mechanisms of action, toxicities and their management (Wata) 11th June 2020 4:00-5:30 PM EAT
  5. Role of Pathology in colorectal cancer management (Kibet) 16th June 2020 4:00-5:30 PM EAT
  6. Role of Surgery in the management of colon and rectal cancers (Jabulani) 18th June 2020 4:00-5:30 PM EAT
  7. Supportive, Palliative and Survivorship care in Prostate Cancer Care (Zippy) 23rd June 2020 4:00-5:30 PM EAT
  8. Role of radiotherapy in the management of rectal cancer (Verna) 25th June 2020 4:00-5:30 PM EAT
  9. Personalized and targeted therapies in colorectal cancers & summary of recommendations: Standard of care protocols (Yesufe) 30th June 2020 4:00-5:30 PM EAT
  10. Evaluation and Treatment approach to advanced colon and rectal cancers (Dinesh) 2nd July 2020 4:00-5:30 PM EAT
  11. Hereditary syndromes associated with colorectal cancers, the management of families with these and implications for individual patients (Chite) 7th July 2020 4:00-5:30 PM EAT
  12. Course Examination in colorectal cancers (Chizi) 9th July 2020 4:00-5:30 PM EAT
  13. Cases and Exam answers discussions in colorectal cancer management (Chizi & Expert Panelists) 10th July 2020 3:00-4:00 PM EAT

Participants should be willing to spend at least 4 hours per week on this online course over a period of 6 weeks. NOTE: The last week has 3 sessions. (Duration 26 hours).

All those interested in registration to this course, please send your information to info@intercancer.com

 

Acknowledgements

ICI Acknowledges that the funding for this preceptorship training has been proudly supported by Roche as part of ICI_Roche Shining Tower Project (STP)

Course Reviews

5

5
4 ratings
  • 5 stars4
  • 4 stars0
  • 3 stars0
  • 2 stars0
  • 1 stars0
  1. 5

    The course was generally well coordinated.

  2. 5

    The course was informative. Thank you

  3. 5

    VERY EDUCATIVE COURSE, MY UNDERSTANDING OF COLORECTAL CANCER DIAGNOSIS AND MANAGEMENT HAS BEEN ENHANCED GREATLY

  4. Colorectal Cancer Preceptorship

    5

    The course was informative, educative with practical scenarios which clinicians do face and I hope the knowledge I gathered here will be a great contribution to the lives of many. Thanks

top
© 2021 International Cancer Institute. All Rights Reserved
X